申请人:NIPPON SODA CO., LTD.
公开号:EP1329454A1
公开(公告)日:2003-07-23
The invention relates to novel thienopyrimidine compounds useful as drugs having a cGMP-specific phosphodiesterase inhibiting effect or the like, specifically thieno[2,3-d]-pyrimidine compounds of the general formula (1), and a process for preparing the same:
wherein R1 is hydrogen or C1-6 alkyl; R2 is optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, or an optionally substituted saturated or unsaturated heterocyclic group containing one to four heteroatoms selected from among N, O and S; R3 is an optionally substituted saturated or unsaturated heterocyclic group containing one to four heteroatoms selected from among N, O and S, (CH2)KC(=O)R6, or CH=CHC(=O)R6; R4 is hydrogen, C1-6 alkyl, hydroxyl, C1-6 alkoxy, halogeno, C1-6 haloalkyl, nitro, or cyano; and R5 is cyano, optionally substituted phenyl, an optionally substituted saturated or unsaturated heterocyclic group containing one to four heteroatoms selected from among N, O and S, or the like.
本发明涉及一种新型噻唑嘧啶化合物,可用作具有cGMP特异性磷酸二酯酶抑制作用等药物,具体为通式(1)的噻吩[2,3-d]-嘧啶化合物,以及其制备方法:其中,R1为氢或C1-6烷基;R2为可选取取代的C3-8环烷基、可选取取代的苯基或含有1-4个异原子(选自N、O和S)的饱和或不饱和杂环基;R3为可选取取代的含有1-4个异原子(选自N、O和S)的饱和或不饱和杂环基、(CH2)KC(=O)R6或CH=CHC(=O)R6;R4为氢、C1-6烷基、羟基、C1-6烷氧基、卤素、C1-6卤代烷基、硝基或氰基;R5为氰基、可选取取代的苯基、可选取取代的含有1-4个异原子(选自N、O和S)的饱和或不饱和杂环基等。